Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy. Chen HW, Kuo YW, Chen CY, Chang CH, et al. Oncologist 2024;29:e498-e506.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chen HW, Kuo YW, Chen CY, Chang CH, et al. Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy. Oncologist 2024;29:e498-e506.
PMID: 38227604